What is the current valuation of the Muscle Wasting Disorders Market?

The Muscle Wasting Disorders Market was valued at 9.21 USD Billion in 2024. Read More

What is the projected market size for the Muscle Wasting Disorders Market by 2035?

The market is projected to reach 20.54 USD Billion by 2035. Read More

What is the expected CAGR for the Muscle Wasting Disorders Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 7.56%. Read More

Which disease type segment holds the largest market share in 2024?

In 2024, the Muscular Dystrophy segment held the largest market share, valued at 2.76 USD Billion. Read More

How does the valuation of Spinal Muscular Atrophy compare to other muscle wasting disorders?

The Spinal Muscular Atrophy segment was valued at 1.45 USD Billion in 2024, indicating a smaller market share compared to Muscular Dystrophy. Read More

What are the leading treatment modalities in the Muscle Wasting Disorders Market?

Drug Therapies, valued at 3.0 USD Billion in 2024, are among the leading treatment modalities. Read More

What is the projected growth for Gene Therapy in the Muscle Wasting Disorders Market?

Gene Therapy is expected to grow from 1.5 USD Billion in 2024 to 3.5 USD Billion by 2035. Read More

Which mechanism of action segment is anticipated to see the highest growth?

The Muscle Growth Stimulators segment, valued at 2.76 USD Billion in 2024, is anticipated to see substantial growth. Read More

What routes of administration are prevalent in the Muscle Wasting Disorders Market?

Intravenous administration, valued at 2.76 USD Billion in 2024, is one of the prevalent routes. Read More

Who are the key players in the Muscle Wasting Disorders Market?

Key players include Roche, Novartis, Bristol-Myers Squibb, and Pfizer, among others. Read More

Muscle Wasting Disorders Market

Muscle Wasting Disorders Market Research Report By Disease Type (Muscular Dystrophy, Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Other Muscle Wasting Disorders), By Treatment Modality (Drug Therapies, Gene Therapy, Physical Therapy and Rehabilitation, Supplements and Nutrition, Other Treatment Modalities), By Mechanism of Action (Anti-inflammatory Agents, Muscle Growth Stimulators, Gene Editing Therapies, Immunomodulators, Other Mechanisms of Action), By Route of Administration (Oral, Intravenous, Intramuscular, Transdermal, Other Routes of Administration) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.56%

2024 Market Size

$ 9.21 Billion

2035 Market Size

$ 20.54 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/21141-HCR | Pages: 100 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Disease Type (USD Billion)
  1. 4.1.1 Muscular Dystrophy
  2. 4.1.2 Spinal Muscular Atrophy
  3. 4.1.3 Amyotrophic Lateral Sclerosis (ALS)
  4. 4.1.4 Myasthenia Gravis
  5. 4.1.5 Other Muscle Wasting Disorders
2. 4.2 Healthcare, BY Treatment Modality (USD Billion)
  1. 4.2.1 Drug Therapies
  2. 4.2.2 Gene Therapy
  3. 4.2.3 Physical Therapy and Rehabilitation
  4. 4.2.4 Supplements and Nutrition
  5. 4.2.5 Other Treatment Modalities
3. 4.3 Healthcare, BY Mechanism of Action (USD Billion)
  1. 4.3.1 Anti-inflammatory Agents
  2. 4.3.2 Muscle Growth Stimulators
  3. 4.3.3 Gene Editing Therapies
  4. 4.3.4 Immunomodulators
  5. 4.3.5 Other Mechanisms of Action
4. 4.4 Healthcare, BY Route of Administration (USD Billion)
  1. 4.4.1 Oral
  2. 4.4.2 Intravenous
  3. 4.4.3 Intramuscular
  4. 4.4.4 Transdermal
  5. 4.4.5 Other Routes of Administration
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck & Co. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DISEASE TYPE
4. 6.4 US MARKET ANALYSIS BY TREATMENT MODALITY
5. 6.5 US MARKET ANALYSIS BY MECHANISM OF ACTION
6. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7. 6.7 CANADA MARKET ANALYSIS BY DISEASE TYPE
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT MODALITY
9. 6.9 CANADA MARKET ANALYSIS BY MECHANISM OF ACTION
10. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY DISEASE TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT MODALITY
14. 6.14 GERMANY MARKET ANALYSIS BY MECHANISM OF ACTION
15. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
16. 6.16 UK MARKET ANALYSIS BY DISEASE TYPE
17. 6.17 UK MARKET ANALYSIS BY TREATMENT MODALITY
18. 6.18 UK MARKET ANALYSIS BY MECHANISM OF ACTION
19. 6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
20. 6.20 FRANCE MARKET ANALYSIS BY DISEASE TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT MODALITY
22. 6.22 FRANCE MARKET ANALYSIS BY MECHANISM OF ACTION
23. 6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
24. 6.24 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT MODALITY
26. 6.26 RUSSIA MARKET ANALYSIS BY MECHANISM OF ACTION
27. 6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
28. 6.28 ITALY MARKET ANALYSIS BY DISEASE TYPE
29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT MODALITY
30. 6.30 ITALY MARKET ANALYSIS BY MECHANISM OF ACTION
31. 6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
32. 6.32 SPAIN MARKET ANALYSIS BY DISEASE TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT MODALITY
34. 6.34 SPAIN MARKET ANALYSIS BY MECHANISM OF ACTION
35. 6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT MODALITY
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY MECHANISM OF ACTION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY DISEASE TYPE
42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT MODALITY
43. 6.43 CHINA MARKET ANALYSIS BY MECHANISM OF ACTION
44. 6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
45. 6.45 INDIA MARKET ANALYSIS BY DISEASE TYPE
46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT MODALITY
47. 6.47 INDIA MARKET ANALYSIS BY MECHANISM OF ACTION
48. 6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
49. 6.49 JAPAN MARKET ANALYSIS BY DISEASE TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT MODALITY
51. 6.51 JAPAN MARKET ANALYSIS BY MECHANISM OF ACTION
52. 6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT MODALITY
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY MECHANISM OF ACTION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
57. 6.57 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT MODALITY
59. 6.59 MALAYSIA MARKET ANALYSIS BY MECHANISM OF ACTION
60. 6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
61. 6.61 THAILAND MARKET ANALYSIS BY DISEASE TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT MODALITY
63. 6.63 THAILAND MARKET ANALYSIS BY MECHANISM OF ACTION
64. 6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
65. 6.65 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT MODALITY
67. 6.67 INDONESIA MARKET ANALYSIS BY MECHANISM OF ACTION
68. 6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
69. 6.69 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT MODALITY
71. 6.71 REST OF APAC MARKET ANALYSIS BY MECHANISM OF ACTION
72. 6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT MODALITY
76. 6.76 BRAZIL MARKET ANALYSIS BY MECHANISM OF ACTION
77. 6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
78. 6.78 MEXICO MARKET ANALYSIS BY DISEASE TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT MODALITY
80. 6.80 MEXICO MARKET ANALYSIS BY MECHANISM OF ACTION
81. 6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
82. 6.82 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT MODALITY
84. 6.84 ARGENTINA MARKET ANALYSIS BY MECHANISM OF ACTION
85. 6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT MODALITY
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY MECHANISM OF ACTION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT MODALITY
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY MECHANISM OF ACTION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT MODALITY
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY MECHANISM OF ACTION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
99. 6.99 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT MODALITY
101. 6.101 REST OF MEA MARKET ANALYSIS BY MECHANISM OF ACTION
102. 6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TREATMENT MODALITY, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TREATMENT MODALITY, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY MECHANISM OF ACTION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.2.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.3.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.4.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.5.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.6.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.7.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.8.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.9.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.10.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.11.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.12.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.13.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.14.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.15.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.16.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.17.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.18.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.19.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.20.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.21.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.22.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.23.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.24.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.25.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.26.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.27.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.28.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.29.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
  3. 7.30.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Muscle Wasting Disorders Market Segmentation

Muscle Wasting Disorders Market By Disease Type (USD Billion, 2025-2035)

Muscular Dystrophy
Spinal Muscular Atrophy
Amyotrophic Lateral Sclerosis (ALS)
Myasthenia Gravis
Other Muscle Wasting Disorders

Muscle Wasting Disorders Market By Treatment Modality (USD Billion, 2025-2035)

Drug Therapies
Gene Therapy
Physical Therapy and Rehabilitation
Supplements and Nutrition
Other Treatment Modalities

Muscle Wasting Disorders Market By Mechanism of Action (USD Billion, 2025-2035)

Anti-inflammatory Agents
Muscle Growth Stimulators
Gene Editing Therapies
Immunomodulators
Other Mechanisms of Action

Muscle Wasting Disorders Market By Route of Administration (USD Billion, 2025-2035)

Oral
Intravenous
Intramuscular
Transdermal
Other Routes of Administration

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”